1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.218
Figure insights for the evolution of cardiac regenerative medicine
Figure 1 | 2017 insights for the evolution of cardiac regenerative medicine. Use of regenerative therapies is supported by the demonstrated renewal capacity of the adult heart and by positive results of different products in animal models. In addition, first-generation stem cell therapeutics have been shown to be safe and modestly beneficial in humans. Important contributions published in 2017 show a more refined research approach and general maturation of the field: demonstration of the capacity of adult mammalian cardiomyocytes to dedifferentiate, proliferate, and redifferentiate2; identification of the important role of the extracellular matrix (ECM) protein agrin3; overcoming the 'one-shot' protocol paradigm4; clinical data supporting paracrine effects of stem cell therapies5; and the first global consensus document of a transnational alliance on cardiac regenerative medicine (TACTICS) with future implications for this field. These advances have challenged the main paradigms of the field medicine and have repositioned old and new biological treatments in the pipeline.
Fernández-Avilés, F. (2018) Novel paradigms in the fight against heart failure
Nat. Rev. Cardiol. doi: /nrcardio